{
    "clinical_study": {
        "@rank": "148106", 
        "arm_group": [
            {
                "arm_group_label": "MK-1293", 
                "arm_group_type": "Experimental", 
                "description": "MK-1293 administered subcutaneously once daily."
            }, 
            {
                "arm_group_label": "Lantus\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "Lantus\u2122 administered subcutaneously once daily."
            }
        ], 
        "brief_summary": {
            "textblock": "This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus\u2122 participants\n      with type 2 diabetes mellitus (T2DM)."
        }, 
        "brief_title": "The Safety and Efficacy of MK-1293 Versus Lantus\u2122 in Participants With Type 2 Diabetes Mellitus (MK-1293-006)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM) as defined by the American Diabetes\n             Association (ADA) or the European Association for the Study of Diabetes (EASD)\n\n          -  hemoglobin A1C of \u226411.0% and requires insulin for glycemic control\n\n          -  Body mass index (BMI) <45 kg/m^2\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis, or has type 1\n             diabetes confirmed with a C-peptide <0.7 ng/mL (0.23 nmol/L)\n\n          -  One or more severe hypoglycemic episodes associated with hypoglycemic seizures, comas\n             or unconsciousness within the past 6 months\n\n          -  History of intolerance or hypersensitivity to Lantus\u2122 or contraindication to Lantus\u2122\n             or one of its excipients based on the label of the country of the investigational\n             site\n\n          -  On a weight loss program within the last 8 weeks\n\n          -  Received injectable incretin-based therapy (e.g., Victoza\u2122, Byetta\u2122) within\n\n        the prior 8 weeks\n\n          -  Bariatric surgery within 12 months prior to signing the informed consent\n\n          -  Likely to require treatment for \u22652 consecutive weeks or repeated courses of\n\n        corticosteroids\n\n          -  Undergone a surgical procedure within 4 weeks prior to signing informed\n\n        consent or has planned major surgery during the study\n\n          -  New or worsening signs or symptoms of coronary heart disease or congestive heart\n             failure within the last 3 months\n\n          -  Presence of any of the following during the last 3 months: acute coronary syndrome,\n             coronary artery intervention, and/or stroke or transient ischemic neurological\n             disorder\n\n          -  Severe peripheral vascular disease\n\n          -  Systolic blood pressure \u2265 160 mm Hg or a diastolic \u226595 mm Hg and blood pressure is\n             not considered likely to be under these limits with an adjustment in antihypertensive\n             medication\n\n          -  Chronic myopathy or a progressive neurological or neuromuscular disorder\n\n          -  Active nephropathy\n\n          -  History of active liver disease (other than non-alcoholic hepatic steatosis),\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  Clinically important hematological disorder (such as aplastic anemia,\n             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  History of malignancy \u22645 years prior to signing informed consent, except for\n             adequately treated basal cell or squamous cell skin cancer, or in situ cervical\n             cancer\n\n          -  History of melanoma, leukemia, lymphoma, or renal cell carcinoma\n\n          -  Hyperthyroidism\n\n          -  On a stable dose of thyroid hormone replacement therapy for <6 weeks\n\n          -  Uses recreational or illicit drugs or has had a recent history (within the last year)\n             of drug or alcohol abuse or dependence\n\n          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs\n\n        during the study, including 14 days following the last dose of study drug\n\n          -  Donated blood products or has had phlebotomy of >300 mL within 8 weeks of signing\n             informed consent, or intends to donate blood products within the projected duration\n             of the study\n\n          -  Poor mental function or any other reason to expect that the participant may\n\n        have difficulty in complying with the requirements of the study\n\n          -  Clinically significant ECG abnormality which exposes the participant to risk by\n             enrolling in the study\n\n          -  Positive urine pregnancy test\n\n          -  Participant is a night shift worker which causes difficulty complying with the\n             overnight fast requirement and has potential for confounding the 7-point SMBG\n             analysis\n\n          -  Participant, as assessed by the investigator, is not appropriate for or does not\n             agree to target a fasting glucose of 70-100 mg/dL [3.9 -5.6 mmol/L]\n\n          -  Has used a formulation of glargine insulin other than Lantus\u2122"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059187", 
            "org_study_id": "1293-006", 
            "secondary_id": "2012-003478-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-1293", 
                "description": "MK-1293 administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.", 
                "intervention_name": "MK-1293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lantus\u2122", 
                "description": "Lantus\u2122 administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.", 
                "intervention_name": "Lantus\u2122", 
                "intervention_type": "Drug", 
                "other_name": "Insulin glargine [rDNA origin]"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glargine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "Call for Information (Investigational Site 2100)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90059"
                    }, 
                    "name": "Call for Information (Investigational Site 2110)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90057"
                    }, 
                    "name": "Call for Information (Investigational Site 2109)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91307"
                    }, 
                    "name": "Call for Information (Investigational Site 2107)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Call for Information (Investigational Site 2101)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33401"
                    }, 
                    "name": "Call for Information (Investigational Site 2113)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68131"
                    }, 
                    "name": "Call for Information (Investigational Site 2105)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37620"
                    }, 
                    "name": "Call for Information (Investigational Site 2108)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Call for Information (Investigational Site 2102)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Call for Information (Investigational Site 2106)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77095"
                    }, 
                    "name": "Call for Information (Investigational Site 2104)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "North Ryde", 
                        "country": "Australia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "Wellington", 
                        "country": "New Zealand"
                    }, 
                    "name": "Merck Sharp & Dohme (New Zealand) Ltd.,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Colombia", 
                "New Zealand", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus\u2122 in Subjects With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants With Confrmed Anti-Insulin Antibodies up to Week 24", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change From Baseline in Participant Hemoglobin A1C Level at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in Participant Body Weight at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Number of Participants Experiencing Hypoglycemia Up to Week 24", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Number of Participants Experiencing an Adverse Event (AE) Up to Week 24", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change From Baseline in Participant Daily Insulin Dose (Units) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change From Baseline in Participant Insulin Dose Per Body Weight (Units/kg) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change From Baseline in Participant 7-Point Self-Monitored Blood Glucose (SMBG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Proportion of Participants With Hemoglobin A1C <7% at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Proportion of Participants With Hemoglobin A1C <6.5% at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}